Clinical Significance of Neuregulin 4, Afamin, and SERPINB1 in Gestational Diabetes Mellitus and Their Relationship with Insulin Resistance
Table 2
Demographic, clinical, and biochemical characteristics of study groups.
GDM
Non-GDM
t
Age (years)
29.5 ± 2.27
29.57 ± 2.94
0.138
0.891
Gestational age (weeks)
25.78 ± 1.36
26.05 ± 1.35
1.099
0.274
BMI (kg/m2)
25.04 ± 2.15
24.95 ± 2.42
0.213
0.831
Newborn weight (g)
3.03 ± 0.53
2.9 ± 0.51
1.294
0.198
HbA1C%
5.00 ± 0.64
4.91 ± 0.56
0.847
0.399
SBP (mmHg)
106.4 ± 8.47
105.3 ± 9.80
0.700
0.486
DBP (mmHg)
74.53 ± 8.72
74.48 ± 8.72
0.032
0.975
Gravidity
2.14 ± 1.13
2.25 ± 1.17
0.528
0.599
Parity
0.98 ± 0.71
1.02 ± 0.83
0.237
0.813
Fasting glucose (mmol/L)
7.8 ± 1.15
7.08 ± 0.57
4.353
<0.001
Fasting insulin (IU/mL)
9.66 ± 4.36
8.29 ± 1.74
2.250
0.026
HOMA-IR
3.42 ± 1.72
2.61 ± 0.6
3.415
0.001
Gestational diabetes mellitus (GDM), body mass index (BMI), hemoglobin A1C (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), and homeostatic model assessment of insulin resistance (HOMA-IR).
